
M. Franco G. Salvoza
Examiner (ID: 7827, Phone: (571)272-4468 , Office: P/1648 )
| Most Active Art Unit | 1648 |
| Art Unit(s) | 1648, 1671, 1672 |
| Total Applications | 792 |
| Issued Applications | 451 |
| Pending Applications | 119 |
| Abandoned Applications | 244 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 9916749
[patent_doc_number] => 20150071955
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-03-12
[patent_title] => 'GB VIRUS C (HEPATITIS G VIRUS) E2 GLYCOPROTEIN AS AN IMMUNOMODULATORY AGENT'
[patent_app_type] => utility
[patent_app_number] => 14/384775
[patent_app_country] => US
[patent_app_date] => 2013-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 27
[patent_figures_cnt] => 27
[patent_no_of_words] => 27070
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14384775
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/384775 | GB virus C (hepatitis G virus) E2 glycoprotein as an immunomodulatory agent | Mar 12, 2013 | Issued |
Array
(
[id] => 9670491
[patent_doc_number] => 20140234354
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-08-21
[patent_title] => 'PORCINE PARVOVIRUS 5B, METHODS OF USE AND VACCINE'
[patent_app_type] => utility
[patent_app_number] => 13/800413
[patent_app_country] => US
[patent_app_date] => 2013-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 15153
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13800413
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/800413 | PORCINE PARVOVIRUS 5B, METHODS OF USE AND VACCINE | Mar 12, 2013 | |
Array
(
[id] => 9545533
[patent_doc_number] => 20140170180
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-06-19
[patent_title] => 'PORCINE PARVOVIRUS 5A, METHODS OF USE AND VACCINE'
[patent_app_type] => utility
[patent_app_number] => 13/796621
[patent_app_country] => US
[patent_app_date] => 2013-03-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 15091
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13796621
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/796621 | PORCINE PARVOVIRUS 5A, METHODS OF USE AND VACCINE | Mar 11, 2013 | Abandoned |
Array
(
[id] => 9838549
[patent_doc_number] => 20150030630
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-01-29
[patent_title] => 'ADJUVANTED FORMULATIONS OF RABIES VIRUS IMMUNOGENS'
[patent_app_type] => utility
[patent_app_number] => 14/382579
[patent_app_country] => US
[patent_app_date] => 2013-03-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 17510
[patent_no_of_claims] => 32
[patent_no_of_ind_claims] => 18
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14382579
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/382579 | ADJUVANTED FORMULATIONS OF RABIES VIRUS IMMUNOGENS | Mar 6, 2013 | Abandoned |
Array
(
[id] => 12306579
[patent_doc_number] => 09938559
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-04-10
[patent_title] => Bismuth-containing concentration agents for microorganisms
[patent_app_type] => utility
[patent_app_number] => 14/391904
[patent_app_country] => US
[patent_app_date] => 2013-03-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14048
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14391904
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/391904 | Bismuth-containing concentration agents for microorganisms | Mar 3, 2013 | Issued |
Array
(
[id] => 10272704
[patent_doc_number] => 20150157700
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-06-11
[patent_title] => 'ADENOVIRAL VECTOR-BASED MALARIA VACCINE'
[patent_app_type] => utility
[patent_app_number] => 14/373574
[patent_app_country] => US
[patent_app_date] => 2013-02-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 39545
[patent_no_of_claims] => 293
[patent_no_of_ind_claims] => 28
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14373574
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/373574 | ADENOVIRAL VECTOR-BASED MALARIA VACCINE | Jan 31, 2013 | Abandoned |
Array
(
[id] => 10233271
[patent_doc_number] => 20150118264
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-04-30
[patent_title] => 'PHARMACEUTICAL COMPOSITION COMPRISING A POLYMERIC CARRIER CARGO COMPLEX AND AT LEAST ONE PROTEIN OR PEPTIDE ANTIGEN'
[patent_app_type] => utility
[patent_app_number] => 14/375215
[patent_app_country] => US
[patent_app_date] => 2013-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 32
[patent_figures_cnt] => 32
[patent_no_of_words] => 86280
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14375215
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/375215 | PHARMACEUTICAL COMPOSITION COMPRISING A POLYMERIC CARRIER CARGO COMPLEX AND AT LEAST ONE PROTEIN OR PEPTIDE ANTIGEN | Jan 30, 2013 | Abandoned |
Array
(
[id] => 10444881
[patent_doc_number] => 20150329895
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-11-19
[patent_title] => 'Methods of Determining Cell Mediated Response'
[patent_app_type] => utility
[patent_app_number] => 14/375854
[patent_app_country] => US
[patent_app_date] => 2013-01-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 21844
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 10
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14375854
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/375854 | Methods of Determining Cell Mediated Response | Jan 29, 2013 | Abandoned |
Array
(
[id] => 9805757
[patent_doc_number] => 20150017703
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-01-15
[patent_title] => 'METHODS FOR INCREASING THE INFECTIVITY OF VIRUSES'
[patent_app_type] => utility
[patent_app_number] => 14/374345
[patent_app_country] => US
[patent_app_date] => 2013-01-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15315
[patent_no_of_claims] => 119
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14374345
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/374345 | METHODS FOR INCREASING THE INFECTIVITY OF VIRUSES | Jan 24, 2013 | Abandoned |
Array
(
[id] => 9930885
[patent_doc_number] => 20150079077
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-03-19
[patent_title] => 'METHODS AND COMPOSITIONS FOR THERAPEUTIC AGENTS'
[patent_app_type] => utility
[patent_app_number] => 14/373930
[patent_app_country] => US
[patent_app_date] => 2013-01-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 16442
[patent_no_of_claims] => 71
[patent_no_of_ind_claims] => 32
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14373930
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/373930 | METHODS AND COMPOSITIONS FOR THERAPEUTIC AGENTS | Jan 24, 2013 | Abandoned |
Array
(
[id] => 10103846
[patent_doc_number] => 09139620
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2015-09-22
[patent_title] => 'Feline morbillivirus and uses thereof'
[patent_app_type] => utility
[patent_app_number] => 13/746947
[patent_app_country] => US
[patent_app_date] => 2013-01-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 45
[patent_figures_cnt] => 45
[patent_no_of_words] => 25439
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 126
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13746947
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/746947 | Feline morbillivirus and uses thereof | Jan 21, 2013 | Issued |
Array
(
[id] => 9838484
[patent_doc_number] => 20150030565
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2015-01-29
[patent_title] => 'PURIFICATION OF FLAVIVIRUSES'
[patent_app_type] => utility
[patent_app_number] => 14/369796
[patent_app_country] => US
[patent_app_date] => 2013-01-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 8606
[patent_no_of_claims] => 34
[patent_no_of_ind_claims] => 10
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14369796
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/369796 | PURIFICATION OF FLAVIVIRUSES | Jan 7, 2013 | Abandoned |
Array
(
[id] => 10946300
[patent_doc_number] => 20140349321
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-11-27
[patent_title] => 'BINDING MOLECULES AGAINST DENGUE VIRUS AND USES THEREOF'
[patent_app_type] => utility
[patent_app_number] => 14/365853
[patent_app_country] => US
[patent_app_date] => 2012-12-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 24
[patent_figures_cnt] => 24
[patent_no_of_words] => 23527
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 10
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14365853
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/365853 | BINDING MOLECULES AGAINST DENGUE VIRUS AND USES THEREOF | Dec 16, 2012 | Abandoned |
Array
(
[id] => 10892565
[patent_doc_number] => 08916176
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2014-12-23
[patent_title] => 'Modified parvovirus having enhanced anti-tumor efficacy'
[patent_app_type] => utility
[patent_app_number] => 13/713889
[patent_app_country] => US
[patent_app_date] => 2012-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 30
[patent_figures_cnt] => 28
[patent_no_of_words] => 17997
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 110
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13713889
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/713889 | Modified parvovirus having enhanced anti-tumor efficacy | Dec 12, 2012 | Issued |
Array
(
[id] => 9739043
[patent_doc_number] => 20140274762
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2014-09-18
[patent_title] => 'MULTIPLEX IMMUNO SCREENING ASSAY'
[patent_app_type] => utility
[patent_app_number] => 13/883339
[patent_app_country] => US
[patent_app_date] => 2012-12-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 42871
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13883339
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/883339 | Multiplex immuno screening assay | Dec 9, 2012 | Issued |
Array
(
[id] => 11480493
[patent_doc_number] => 09587025
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-03-07
[patent_title] => 'Non-sialylated anti-inflammatory polypeptides'
[patent_app_type] => utility
[patent_app_number] => 14/368701
[patent_app_country] => US
[patent_app_date] => 2012-12-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 8
[patent_no_of_words] => 9319
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 72
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14368701
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/368701 | Non-sialylated anti-inflammatory polypeptides | Dec 9, 2012 | Issued |
Array
(
[id] => 8853203
[patent_doc_number] => 20130142878
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2013-06-06
[patent_title] => 'PEPTIDE PARTICLE FORMULATION'
[patent_app_type] => utility
[patent_app_number] => 13/691234
[patent_app_country] => US
[patent_app_date] => 2012-11-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 24054
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13691234
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/691234 | PEPTIDE PARTICLE FORMULATION | Nov 29, 2012 | Abandoned |
Array
(
[id] => 9607655
[patent_doc_number] => 08784820
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2014-07-22
[patent_title] => 'Plasminogen-activating antibody, use and producing method thereof and agent including the same'
[patent_app_type] => utility
[patent_app_number] => 13/668052
[patent_app_country] => US
[patent_app_date] => 2012-11-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 8
[patent_no_of_words] => 4539
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 69
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13668052
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/668052 | Plasminogen-activating antibody, use and producing method thereof and agent including the same | Nov 1, 2012 | Issued |
Array
(
[id] => 12466326
[patent_doc_number] => 09987350
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2018-06-05
[patent_title] => Antigens and vaccines directed against human enteroviruses
[patent_app_type] => utility
[patent_app_number] => 14/402495
[patent_app_country] => US
[patent_app_date] => 2012-11-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 25
[patent_no_of_words] => 17732
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14402495
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/402495 | Antigens and vaccines directed against human enteroviruses | Oct 31, 2012 | Issued |
Array
(
[id] => 15818831
[patent_doc_number] => 10634589
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-04-28
[patent_title] => Methods of reducing or eliminating protein modification and degradation arising from exposure to UV light
[patent_app_type] => utility
[patent_app_number] => 14/353704
[patent_app_country] => US
[patent_app_date] => 2012-10-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 16
[patent_no_of_words] => 20205
[patent_no_of_claims] => 34
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 168
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14353704
[rel_patent_id] =>[rel_patent_doc_number] =>) 14/353704 | Methods of reducing or eliminating protein modification and degradation arising from exposure to UV light | Oct 24, 2012 | Issued |